Prostate cancer drug trialed to reduce steroids in kids with rare hormone disorder
NCT ID NCT02574910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a drug called abiraterone acetate (normally used for prostate cancer) in 4 children with congenital adrenal hyperplasia (CAH). The goal was to see if it could lower high male hormone levels and reduce the need for strong steroid medications that can slow growth. The study was stopped early because not enough children signed up, so no clear conclusions could be drawn.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC 21-HYDROXYLASE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Medical Center
Dallas, Texas, 75235, United States
-
National Institutes of Health
Bethesda, Maryland, 20892-1932, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple saliva test replace blood draws for hormone monitoring?
- New program aims to smooth healthcare transition for teens with rare hormone disorder
- New hope for CAH: drug may slash steroid use
- New hope for toddlers with rare hormone disorder?
- Italian study checks how well newborn screening detects rare hormone disorder
- New hormone treatment shows promise for rare adrenal disorder